Day‐to‐day variability of porcine lente, insulin glargine 300 U/ mL and insulin degludec in diabetic dogs

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Diabetes ◽

10.2337/db18-1057-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1057-P

Author(s):

SEAN D. SULLIVAN ◽

TIMOTHY S. BAILEY ◽

RONAN ROUSSEL ◽

FANG L. ZHOU ◽

ZSOLT BOSNYAK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Clinical Outcomes ◽

Real World ◽

Insulin Detemir ◽

Insulin Degludec ◽

Subgroup Analyses

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1400011 ◽

2017 ◽

Vol 18 (17) ◽

pp. 1789-1798 ◽

Cited By ~ 14

Author(s):

Xiaoling Cai ◽

Xueying Gao ◽

Wenjia Yang ◽

Linong Ji

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Meta Analysis ◽

Insulin Degludec

Acylated-based long-acting insulin analogues: Is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes

Diabetes & Metabolism ◽

10.1016/j.diabet.2014.10.001 ◽

2014 ◽

Vol 40 (6) ◽

pp. 483-484 ◽

Cited By ~ 1

Author(s):

L. Monnier ◽

C. Colette ◽

D. Owens

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Insulin Analogues ◽

Insulin Degludec ◽

Insulin Antibody ◽

Daily Insulin ◽

Acting Insulin ◽

Long Acting

Insulin Degludec Results in Consistently Lower Rates of Nocturnal Hypoglycemia Despite Lower FPG Levels Compared to Insulin Glargine in Seven Trials with T1DM or T2DM

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2012.07.404 ◽

2012 ◽

Vol 36 (5) ◽

pp. S58-S59

Author(s):

David L. Russell-Jones ◽

Stefano Del Prato ◽

Mari-Anne Gall ◽

Nathan Lassota ◽

Michaela Diamant

Keyword(s):

Insulin Glargine ◽

Insulin Degludec ◽

Nocturnal Hypoglycemia

Clinical Research of Insulin Glargine U300 basal‐bolus therapy and Insulin Degludec/Aspart Co‐Formulation in Type 2 Diabetes Mellitus: A Real World Experience (CRIGDA Study)

International Journal of Clinical Practice ◽

10.1111/ijcp.14377 ◽

2021 ◽

Author(s):

Savas Volkan Kisioglu ◽

Ahmet Suat Demir ◽

Damla Tufekci ◽

Yasemin Emur Gunay ◽

Hulya Coskun ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Clinical Research ◽

Insulin Glargine ◽

Real World ◽

Insulin Degludec ◽

Basal Bolus

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Diabetes & Metabolism ◽

10.1016/j.diabet.2018.11.004 ◽

2019 ◽

Vol 45 (4) ◽

pp. 330-340 ◽

Cited By ~ 3

Author(s):

D.R. Owens ◽

T. S Bailey ◽

C.G. Fanelli ◽

J.-F. Yale ◽

G.B. Bolli

Keyword(s):

Insulin Glargine ◽

Clinical Relevance ◽

Insulin Degludec ◽

Clinical Interpretation

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

Diabetes Metabolic Syndrome and Obesity Targets and Therapy ◽

10.2147/dmso.s63878 ◽

2014 ◽

pp. 225

Author(s):

Samit Ghosal ◽

Binayak Sinha ◽

Kalyan Gangopadhyay

Keyword(s):

Insulin Glargine ◽

Effective Treatment ◽

Case Reports ◽

Insulin Degludec ◽

High Doses

A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes

Endocrine Journal ◽

10.1507/endocrj.ej16-0294 ◽

2017 ◽

Vol 64 (2) ◽

pp. 133-140 ◽

Cited By ~ 8

Author(s):

Tatsuhiko Urakami ◽

Yusuke Mine ◽

Masako Aoki ◽

Misako Okuno ◽

Junichi Suzuki

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Crossover Study ◽

Insulin Degludec ◽

Efficacy And Safety ◽

Randomized Crossover Study

7.3. Lower Within-Subject Variability in Mean Blood Glucose Concentration with Insulin Degludec vs. Insulin Glargine: A Meta-Analysis of Patients with T2D (914-P)

Nederlands Tijdschrift voor Diabetologie ◽

10.1007/s12467-013-0054-2 ◽

2013 ◽

Vol 11 (3) ◽

pp. 99-100

Author(s):

Luigi F. Meneghini ◽

Stewart B. Harris ◽

Marc Evans ◽

Søren Rasmussen ◽

Thue Johansen ◽

...

Keyword(s):

Blood Glucose ◽

Insulin Glargine ◽

Glucose Concentration ◽

Blood Glucose Concentration ◽

Meta Analysis ◽

Insulin Degludec ◽

Subject Variability ◽

Mean Blood Glucose ◽

Within Subject Variability

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in Health ◽

10.1016/j.jval.2013.08.685 ◽

2013 ◽

Vol 16 (7) ◽

pp. A442

Author(s):

B. Chubb ◽

M. Evans ◽

M. Wolden ◽

T. Christensen ◽

J. Gundgaard

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

United Kingdom ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Type 1 Diabetes Mellitus ◽

Insulin Degludec ◽

The United Kingdom ◽

Basal Bolus